Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced on August 10, 2026, that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), a first-in-class candidate for multiple sclerosis (MS). This clearance allows the company to advance the drug into Phase 2 clinical development, a critical step toward potential market approval.
The upcoming Phase 2 study will be a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS. Clinical and radiological measures will be used to assess outcomes. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as soon as possible.
Lucid-MS is distinct from existing MS therapies. Most current treatments focus on modulating the immune system to reduce inflammation and attacks on myelin, the protective sheath around nerve fibers. In contrast, Lucid-MS aims to provide neuroprotection by inhibiting demyelination, the process that damages myelin. It targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have shown that Lucid-MS can prevent and even reverse myelin breakdown, which could potentially alter the course of the disease, not just manage symptoms.
The FDA clearance is based on promising early data. In Phase 1 trials, Lucid-MS demonstrated a favorable safety profile and was well tolerated in healthy participants. This milestone is significant for Quantum BioPharma, which is developing Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc. The company’s lead compound is patented and represents a novel chemical entity.
The approval also has broader implications for the MS community. Approximately 2.8 million people worldwide are affected by MS, according to the National Multiple Sclerosis Society. Current therapies can reduce relapse rates and slow progression, but they do not repair existing myelin damage. If successful in Phase 2 and subsequent trials, Lucid-MS could offer a new approach that directly targets the underlying pathophysiology, potentially improving long-term outcomes for patients.
Financially, Quantum BioPharma reported having over $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may provide runway for the trial. The company is also diversified with investments in Unbuzzd Wellness Inc., retaining a 19.84% stake and royalty payments on sales of its OTC product.
While the path to approval is lengthy and uncertain, the FDA’s clearance to proceed with Phase 2 is a positive signal. It validates the scientific rationale behind Lucid-MS and moves the candidate closer to potential clinical use. For investors and patients, this development underscores the progress in exploring neuroprotective strategies for MS.
For more information, the full press release is available at https://ibn.fm/HyWYH. The company’s latest updates can be found in its newsroom at https://ibn.fm/QNTM.
